Brain Cancer section

Brain Cancer News and Features

Targeting a unique receptor promising for glioblastoma multiforme

Glioblastoma multiforme (GBM) is one of the most lethal primary brain tumors, but new therapeutic strategies are being investigated.

Finding keys to drug therapy resistance in glioblastoma

Finding keys to drug therapy resistance in glioblastoma

Researchers have found one key as to why certain glioblastomas are resistant to drug therapy, and the answer lies in a tumor's epigenetic signature.

Repurposing antidepressant may target new medulloblastoma pathway

New research suggests that an antidepressant medication, repurposed, could target a novel molecular pathway that causes an aggressive form of medulloblastoma.

Brain mets: Time for a new approach

Brain mets: Time for a new approach

A blue-ribbon team of national experts stated that professional pessimism and out-of-date myths rather than current science may compromise the care of patients with brain cancer.

Triple therapy revs up immune system against a common brain tumor

A triple therapy for glioblastoma, consisting of two types of immunotherapy and targeted radiation, has significantly prolonged the survival of mice with these brain cancers, according to a new report.

Brain Cancer Videos

Brain Cancer Clinical Trials

New drug for multiple myeloma to begin clinical trial

A new drug in development, known as DTP3, has killed myeloma cells in laboratory tests in human cells and mice.

Achieving clinical trial participation through cooperative networks

Clinical trials could benefit from a greater number of participants with a dedicated cooperative network to support rural community cancer centers.

Prior cancer exclusion criteria may stymie potential of lung cancer clinical trials

A history of prior cancer can exclude many individuals from participation in clinical trails related to lung cancer, even when the prior cancer is unlikely to interfere with treatment outcomes.

PD-L1 a possible immunotherapy target in mesothelioma

Approximately one fifth of patients with malignant pleural mesothelioma have cancer cells that express a protein called programmed cell-death ligand 1 (PD-L1), which has been associated with poorer outcomes.

Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone

Targeting BRAF V600E/K mutation-positive melanoma with dabrafenib in combination with trametinib achieves longer overall survival and impoved response rates, compared to treatment with vemurafenib alone.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs